Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 6Colorectal Neoplasms 4Carcinoma, Transitional Cell 4Non-Muscle Invasive Bladder Neoplasms 3Neoplasm Metastasis 3Colonic Neoplasms 3Anus Neoplasms 3Sarcoma 2Rectal Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Carcinoma in Situ 2Virus Diseases 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Neoplasms by Site 1Neoplasm Recurrence, Local 1Nasopharyngeal Carcinoma 1Mycobacterium Infections 1Head and Neck Neoplasms 1Epstein-Barr Virus Infections 1Disease 1Dermatitis 1Carcinoma, Hepatocellular 1Adenoviridae Infections 1

Interventions

valrubicin 1Oncolytic Virotherapy 1Mitomycin 1Interferons 1Gemcitabine 1Fluorescent Antibody Technique 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Virus Diseases × Mitomycin × Clear all
NCT01438112 2021-04-14

BOND

CG Oncology, Inc.

Phase 2/3 Terminated
22 enrolled
Genitourinary

Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡